相关实验视频

Updated: Jul 12, 2025

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

利提菲利马布 (BIIB 059) 的开发用于皮肤和全身性红血性狼

Young Min Cho¹, Richard Furie¹

¹Division of Rheumatology, 865 Northern Boulevard Suite, 302 Great Neck, NY 11021, USA.

|October 25, 2023

概括

利提菲利马布有效地向狼患者的血细胞状树突细胞 (pDCs),抑制关键的炎症途径. 这种试验性疗法在治疗全身性红斑狼 (SLE) 和皮肤性红斑狼 (CLE) 中表现有前途.

科学领域:

免疫学免疫学免疫学
类风湿病学类风湿病学
皮肤病学皮肤病学

背景情况:

等离子体树突细胞 (pDCs) 是系统性红斑狼 (SLE) 和皮肤性红斑狼 (CLE) 病原体的核心.
由pDCs产生的I型干扰素 (IFN-I) 在狼中发挥着关键作用.
针对pDCs代表了狼的潜在治疗策略.

研究的目的:

审查用于SLE和CLE的litifilimab (BIIB 059) 的开发计划.
评估利提菲利马布在狼患者的疗效和安全性.
确认pDCs和IFN-I在狼病原发生中的作用.

主要方法:

利提菲利马布是一种人性化的单克隆抗体,针对pDCs的BDCA2.
利提菲利马布的BDCA2结合抑制了IFN-I和IFN-III的产生.
第I期和第II期LILAC试验的A和B部分对SLE和CLE患者的litifilimab进行了评估.

主要成果:

第一阶段和第二阶段的试验在SLE和CLE患者中都达到了主要终点.
利提菲利马布证明抑制了IFN-I和IFN-III的产生.
这些结果强化了pDCs和IFN-I在狼中的重要性.

结论:

利提菲利马布是SLE和CLE的有前途的治疗候选药物.
药物的作用机制针对狼的关键途径.
目前正在进行III期试验,以进一步评估litifilimab的潜力.

关键词:

在Lilac的审判中.这样,我们就有了anifrolumab.皮肤性红血性狼利提菲利马布 (Lithifilimab) 是一种有毒的药物.血细胞状 denditric 细胞.系统性红血性狼 (Systemic Lupus Erythematosus) 是一种全身性狼.治疗策略是一种治疗策略.第一种类型的干扰子干扰子.

更多相关视频

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...